[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415517":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":24,"centralContacts":29,"locations":38,"responsibleParty":62,"collaborators":7,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":7,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":7,"enrollmentInfo":73,"targetDuration":7,"studyType":76,"phases":7,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",null,[9,12,15,18,21],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Data collection for parameters of organ damage (cardiac and renal blood markers)","Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin\u002Fcreatinine and protein\u002Fcreatinine ratio in urine.",{"type":6,"name":13,"description":14,"armGroupLabels":7,"otherNames":7},"Data collection for blood pressure (BP)","Clinic blood pressure and 24hour BP Measurements",{"type":6,"name":16,"description":17,"armGroupLabels":7,"otherNames":7},"Home-based blood pressure management (substudy)","Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.",{"type":6,"name":19,"description":20,"armGroupLabels":7,"otherNames":7},"Biomarker Profiles (substudy)","Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).",{"type":6,"name":22,"description":23,"armGroupLabels":7,"otherNames":7},"Data collection on patient reported outcomes","Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )",[25],{"name":26,"affiliation":27,"role":28},"Thenral Socrates, Dr. med.","Medical Outpatient Department and Hypertension Clinic, University Hospital BaselUni","PRINCIPAL_INVESTIGATOR",[30,34],{"name":26,"role":31,"phone":32,"phoneExt":7,"email":33},"CONTACT","+41 61 328 6647","thenral.socrates@usb.ch",{"name":35,"role":31,"phone":36,"phoneExt":7,"email":37},"Thilo Burkard, Dr. med.","+41 61 328 7738","thilo.burkard@usb.ch",[39],{"facility":40,"status":41,"city":42,"state":7,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Medical Outpatient Department and Hypertension Clinic, University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":47,"coordinates":48},"Point",[49,50],7.57327,47.55839,{"lat":50,"lon":49},[53,54,55,58,60],{"name":26,"role":31,"phone":32,"phoneExt":7,"email":33},{"name":26,"role":28,"phone":7,"phoneExt":7,"email":7},{"name":56,"role":57,"phone":7,"phoneExt":7,"email":7},"Michael Mayr, PD Dr. med.","SUB_INVESTIGATOR",{"name":59,"role":57,"phone":7,"phoneExt":7,"email":7},"Irene Hösli, Prof. Dr. med.",{"name":61,"role":57,"phone":7,"phoneExt":7,"email":7},"Olav Lapaire, Prof. Dr. med.",{"type":63,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100415517","swiss-postpartum-hypertension-cohort-100415517",false,"NCT04690660","Swiss Postpartum Hypertension Cohort","Swiss Postpartum Hypertension Cohort (Swiss-PPHT)","Inclusion Criteria:\n\n* all women with hypertensive disorders of pregnancy\n* postpartum hypertension (blood pressure measurements of systolic ≥140 and\u002For diastolic ≥ 90mmHg or antihypertensive therapy within the first 14 days after delivery)\n* women with preexisting hypertension or\n* women on antihypertensive medication\n\nExclusion Criteria:\n\n* delivery \\> 14 days\n* lack of consent to participate in the study, language barriers or lack of general understanding","FEMALE","18 Years",{"count":74,"type":75},480,"ESTIMATED","OBSERVATIONAL","This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors\u002Frisk factors associated with long term cardiovascular and renal risk.\n\nCurrent disease management strategies will be evaluated.",[79],"Postpartum Hypertension (PPHT)",[81,82,83,84,85,86],"Pregnancy Induced Hypertension (PIH)","Home Blood Pressure Monitoring (HBPM)","Office Blood Pressure Monitoring (OBPM)","Automated Office Blood Pressure Measurement (AOBPM)","Gestational Hypertension","HekaHealth Self-Measured Blood Pressure (SMBP) App","2025-05-21",{"date":89,"type":90},"2025-05-28","ACTUAL",{"date":92,"type":90},"2020-06-04",{"date":94,"type":75},"2030-05",{"name":5,"class":6},1]